Loading...
Loading...
Impax Laboratories
IPXL today announced
that it is commencing shipment of Oxymorphone Hydrochloride
Extended-Release Tablets, through Global Pharmaceuticals, Impax's
generics division.
In June 2010, Impax reached agreement with Endo Pharmaceuticals and
Penwest Pharmaceuticals (collectively Endo) to settle U.S. patent
litigation with regard to the production and sale of its Oxymorphone
Hydrochloride Extended-Release Tablets approved by the U.S. Food and
Drug Administration (FDA) as therapeutically equivalent to the original
formulation of OPANA® ER. Under the terms of the settlement,
Endo agreed to grant Impax a license to sell Impax's approved product on
January 1, 2013.
As a company whose mission is
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in